{
    "clinical_study": {
        "@rank": "105817", 
        "arm_group": [
            {
                "arm_group_label": "Acupuncture", 
                "arm_group_type": "Experimental", 
                "description": "Acupuncture treatment once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care."
            }, 
            {
                "arm_group_label": "Sham acupuncture", 
                "arm_group_type": "Sham Comparator", 
                "description": "Sham acupuncture once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective randomized controlled trial to obtain preliminary data for the design\n      of a future definitive efficacy study. A randomized controlled trial is needed because\n      comparison to historical data would be biased. The investigators will use sham acupuncture\n      as the control to account for effect from attention from and interaction with the therapist."
        }, 
        "brief_title": "Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 21 or above (those age below 21 are usually treated in the Pediatric Transplant\n             Service)\n\n          -  Diagnosis of multiple myeloma\n\n          -  Scheduled to receive conditioning chemotherapy followed by upfront or salvage\n             autologous peripheral blood hematopoietic stem cell transplantation\n\n        Exclusion Criteria:\n\n          -  Absolute neutrophil count less than 200/microliter\n\n          -  Platelet count less than 20,000/microliter\n\n          -  Acupuncture treatment in the preceding 4 weeks prior to Day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811862", 
            "org_study_id": "13-038"
        }, 
        "intervention": [
            {
                "arm_group_label": "Acupuncture", 
                "description": "Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.", 
                "intervention_name": "Acupuncture", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Sham acupuncture", 
                "description": "Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.", 
                "intervention_name": "Sham acupuncture", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acupuncture", 
            "Hematopoietic stem cell transplantation (HSCT)", 
            "13-038"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Gary Deng, MD, PhD", 
                "phone": "646-888-0815"
            }, 
            "contact_backup": {
                "last_name": "Sergio Giralt, MD", 
                "phone": "212-639-6009"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center 1275 York Avenue"
            }, 
            "investigator": {
                "last_name": "Gary Deng, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients: A Pilot Study", 
        "overall_contact": {
            "last_name": "Gary Deng, MD PhD", 
            "phone": "646-888-0841"
        }, 
        "overall_contact_backup": {
            "last_name": "Sergio Giralt, MD", 
            "phone": "212-639-6009"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Gary Deng, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In patients undergoing chemotherapy prior to hematopoietic stem cell transplantation. The primary endpoint is the area-under-curve (AUC) for MDASI total score from Day -2 to Day 5. MDASI scores are assessed daily by having the patient fill out the questionnaire. Severity is assessed for the 13 core MDASI symptom items (pain, fatigue, nausea, disturbed sleep, distress etc..) AUC for MDASI total score from Day -2 to Day 5 will be compared between the acupuncture group and the sham acupuncture group.", 
            "measure": "whether acupuncture reduces common symptoms", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811862"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Effect size for each symptom will be calculated descriptively. To determine whether baseline characteristics predict response to acupuncture, each will be added as an interaction term to the primary model. The following predictors will be explored: inpatient vs outpatient treatment, upfront vs. salvage transplantation, age, baseline MDASI score, pro-inflammatory cytokine levels, and use of symptom control medications (yes / no).", 
            "measure": "to assess the effect size for each symptom", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}